238 Chapter 11 Table 1. Continued Reference Year Country Study Design Patient Inclusion Period Reasons for Patient Exclusion No. of Subjects No. of Genes Investigated Aim of the Study Start End Lee et al. 30 2019 Korea CH 2004 2008 - 15 409 Analyzing genetic mutations which may be presage PM. Nagahara et al. 31 2011 Japan CH 1993 2000 Chemotherapy or radiotherapy before surgery. 113 1 To investigate if Kif18A has a role in the progression of CRC. Prasanna et al. 45 2018 Australia CH 01/2005 12/2015 - 5967 2 To explore the outcome of patients with mCRC based on their site of metastases at diagnosis and to explore the association between tumor characteristics and site of metastases. Roberto et al. 46 2020 Italy CH 2008 2019 - 207 1 To evaluate the outcome of right CRC patients according to BRAF status and the treatment performed. Sakuraba et al. 32 2009 Japan CH - - - 38 1 To evaluate the correlation between Tip60 expression and the clinicopathological findings. Sasaki et al. 33 2016 Japan CH 02/2006 10/2011 Previous chemotherapy for advanced disease. 526 3 To compare the prognostic impact of modern chemotherapy or anti-EGFR monoclonal antibody between CRC patients with and without PM. Sayagués et al. 34 2018 Spain CH - - - 87 4 To investigate the frequency of mutations in primary sCRC tumors and their impact on patient progression-free survival and overall survival.
RkJQdWJsaXNoZXIy MTk4NDMw